diabetes : Poxel’s Novel Anti-diabetic Agent ...

Search for the latest updates on diabetes

News

Poxel's Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial Business Wire via Yahoo! Finance  - 41 minutes
BOSTON--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, today ...

Current diabetes news »

Search for the latest updates on diabetes

Manage alerts  ·   Privacy Policy

 

Tip: To search for an exact phrase, put quotation marks around two or more words.

 

You received this email because you subscribed to Yahoo! Search.